How to Build a Women's Health App: Cost, Features, and What Clinicians Need

A fertility clinic director contacts us after spending nine months with a vendor who promised a patient-facing IVF protocol tracking app. The vendor delivered a generic period tracker with a custom logo. It could not ingest lab values from the clinic's EMR, could not show follicle monitoring data from the sonographer's workflow, and could not push medication reminders tied to a specific retrieval date. The clinic's nurses were still texting patients individually. The vendor contract had no performance clauses.

This is the scenario that sends fertility clinics, employer wellness directors, and digital health startups to a custom build. Not because Flo or Clue are bad products. They are excellent products for individual cycle tracking. Custom builds become necessary when the population, the integration, or the clinical claim falls outside what a consumer app can support.

Here is what building a custom women's health app actually costs, what it requires architecturally, and where most builders get it wrong.

How much does it cost to build a women's health app?

A women's health MVP with cycle tracking, HIPAA-compliant data handling, and reproductive data privacy architecture costs $70K-$110K and takes 14-18 weeks. A full platform with fertility tracking, prenatal support, telehealth, and wearable sync runs $160K-$280K in 28-40 weeks. Enterprise builds with EHR integration and clinical decision support start at $400K.

The primary cost drivers are the number of health domains covered (cycle tracking only versus cycle plus fertility plus prenatal), whether the app makes clinical claims that require FDA SaMD clearance, and how deep the wearable sensor integration goes.

Who actually builds a custom women's health app?

Off-the-shelf period tracking apps handle consumer cycle logging well. Four operator types consistently hit the ceiling of what consumer apps can do.

Employer wellness programs that want to offer cycle tracking as part of a women's health benefit run into the same wall every time. Flo and Clue are consumer apps. They do not integrate with your identity provider. They cannot surface aggregate utilization data by employee cohort without exposing individual health data. They cannot become a line item in your ERISA-compliant benefits package. And post-Dobbs, offering a consumer period app to your employee base without controlling where that data goes creates legal exposure that your HR legal team will reject. An employer-built or employer-contracted custom app owns the data architecture, the privacy controls, and the benefit administration layer.

Fertility clinics building patient-facing IVF protocol apps need something that consumer apps never built: a clinical data model. IVF patients need to track follicle counts from ultrasound appointments, medication dosages tied to a stimulation protocol, lab values from bloodwork, and retrieval timing tied to an hCG trigger. That data should come from the clinic's EMR, not from the patient typing numbers into a log. A consumer cycle tracker cannot ingest HL7 FHIR resources from an Epic or Cerner instance. A custom build can.

Health plans offering women's health digital engagement programs for their member population need a different product from what any consumer app provides. The health plan needs a platform that manages a defined population (their enrolled members), generates outcomes data at the cohort level, and participates in their care coordination workflow. They also need a BAA with the software vendor that meets their payer-specific compliance requirements, not a consumer app's generic terms of service.

Digital health startups building in the reproductive health space where post-Roe data privacy architecture is itself a market differentiator. A startup building a women's health platform for a health system, an employer, or a clinical network needs to be able to show its procurement team that the platform does not use ad-tech SDKs, does not send reproductive health data to third-party analytics vendors, and has a documented law enforcement data request policy. That is not a configuration option in Flo. It is a first-principles architecture decision that must be made before the first line of code is written.

Flo, Clue, and Natural Cycles vs. custom women's health software

Before you scope a custom build, you should know precisely when these three products stop working and what they cost.

Flo is the market leader in consumer period and cycle tracking. It offers cycle prediction, symptom logging, ovulation window estimates, and a pregnancy mode. Flo Premium costs $13.99/month or $59.99/year. It is the right choice when you want to offer individual women a high-quality personal health tracking experience with no clinical or employer integration requirements. Flo's anonymous mode received FDA marketing authorization in 2023 for privacy-preserving health data features. The product itself makes no contraceptive or diagnostic claims and therefore does not require clearance for cycle tracking.

Clue is the strongest research-backed consumer option. Founded in Berlin, it has a documented clinical research partnership program and publishes peer-reviewed research on menstrual cycle data. Clue Plus costs $4.99/month or $29.99/year. It is the right choice for users who want a data-forward experience and prefer a product with visible scientific rigor. Like Flo, it is a consumer app with no employer integration or clinical data model.

Natural Cycles occupies a different category. It is FDA-cleared (510(k) K173542, 2018) as a contraceptive method based on basal body temperature tracking. It makes a specific clinical claim: that its algorithm, used correctly, prevents pregnancy with a stated effectiveness rate. Natural Cycles costs $12.99/month or $79.99/year. It is the right choice for women who want a hormone-free digital contraceptive method and are willing to take daily temperature readings. It is not a general women's health platform.

Build custom when any of the following are true:

1. You need employer SSO, HRIS integration, or aggregate utilization reporting. None of these products offer it.
2. You are serving a clinical population whose data must flow to or from an EHR. Consumer apps have no clinical data model.
3. You need to control exactly where reproductive health data goes. Consumer apps use third-party analytics and advertising infrastructure that you cannot audit or control.
4. You are making contraceptive efficacy claims, diagnostic claims, or treatment recommendations. That triggers FDA SaMD classification. Consumer apps avoid these claims deliberately.
5. Your employer, health plan, or clinical governance structure requires a signed BAA that meets your specific compliance requirements, not a consumer app's standard privacy policy.

Women's health app features: V1, V2, V3

V1: Launch (14-18 weeks, $70K-$110K)

One note on notifications: this is where many builders make a privacy error. A push notification delivered to a lock screen is visible to anyone who picks up the phone. Notification payloads that include cycle dates, pregnancy status, or fertility data create reproductive health exposure outside the app's secure environment. The correct architecture sends a generic reminder and surfaces the health data only after the user authenticates inside the app.

V2: Growth (adds 14-20 weeks, $80K-$160K)

Wearable integration is consistently underestimated. Apple HealthKit, Google Health Connect, and the Oura Ring API each have different data models, different permission flows, and different update frequencies. A complete wearable sync implementation that handles all three, reads BBT and HRV reliably, and reconciles data conflicts correctly adds $20K-$35K to the build. Teams that scope this as a two-week feature discover the reality four weeks into implementation.

V3: Scale (adds 18+ weeks, $120K+)

Reproductive data privacy: what most builders get wrong

Most digital health builders treat HIPAA compliance as the full picture of health data privacy. For women's health apps specifically, HIPAA is necessary but not sufficient. The risk landscape changed in 2022.

The Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization (2022) eliminated federal constitutional protection for abortion. In several states, abortion is now a criminal act, and the legal mechanisms that could be used to identify someone who sought reproductive care include subpoenas for digital health data. Menstrual cycle dates, pregnancy status, fertility treatment records, and location data from health apps have become potentially discoverable in criminal investigations in certain jurisdictions.

This creates a specific risk for reproductive health apps that is distinct from standard HIPAA obligations. HIPAA applies to Covered Entities and Business Associates: healthcare providers, health plans, and their vendors. A consumer wellness app that is not affiliated with a covered entity is not a Covered Entity and is not directly bound by HIPAA. That means the FTC Act, not HIPAA, governs its data practices.

The FTC has been active here. In 2021, the FTC brought an enforcement action against Flo Health for sharing user health data with third-party analytics vendors including Facebook and Google despite privacy policy representations to the contrary. The settlement required Flo to obtain user consent before sharing health data and to obtain third-party audits of its data practices. The FTC's Health Breach Notification Rule also applies to vendors of personal health records who are not HIPAA-covered entities.

Georgetown Law's O'Neill Institute and the Electronic Frontier Foundation have both published research on how menstrual tracking data could be used in reproductive health criminal investigations. The EFF's 2022 analysis identified specific data categories of concern: period start and end dates, pregnancy tests logged in the app, ovulation estimates, and location data from the device while using the app.

The architecture response to this risk landscape has four components:

Reproductive health data stored in a dedicated encrypted partition, separate from general app data and accessible only through authenticated API endpoints. No third-party analytics SDKs (Meta Pixel, Google Analytics, AppsFlyer, Branch) that receive reproductive health data in any form, identifiable or otherwise. A documented and tested user-initiated data deletion flow that removes reproductive health data from all system layers, including backups, within a defined time window. A written law enforcement data request policy that specifies what data the app holds, in what form, and the legal standard the company requires before disclosing any user data.

This is not a setting or a configuration. It is a foundational data architecture decision. It must be made before the first API endpoint is designed, not retrofitted after launch when procurement teams start asking questions.

FDA SaMD classification for women's health apps

Most women's health apps are outside FDA scope. The distinction is whether the app makes a clinical claim.

A consumer cycle tracking app that logs period dates, predicts the next cycle, and shows a fertility window estimate makes no clinical claim. It is a personal health tool. The FDA's Digital Health Center of Excellence (FDA DHCE) has published guidance confirming that general wellness apps that promote healthy lifestyle choices, including cycle awareness, are not Software as a Medical Device (SaMD) and do not require FDA clearance.

Natural Cycles changed the landscape in 2018. It received FDA 510(k) clearance (K173542) as a contraceptive method, the first digital contraceptive cleared by the FDA. The clearance is specific: Natural Cycles is cleared to be used as a method of contraception to prevent pregnancy in adult women. That is a clinical claim. The clearance applies to that specific claim and that specific algorithm, tested with specific data and validated against a specific effectiveness standard.

If your app makes any of the following claims, you are likely building a Class II SaMD:

A contraceptive efficacy claim (this app can be used to prevent pregnancy). A diagnostic claim (this app detects signs of PCOS, endometriosis, or hormonal imbalance). A treatment recommendation (this app recommends medication timing, dosage, or clinical intervention based on symptom data). A claim that the app monitors a medical condition or is intended for use in the management of a disease.

The path to clearance for a novel device type is the De Novo request, not a 510(k), because there is no predicate device. The De Novo process for a digital health SaMD typically takes 12-18 months and costs $200K-$500K in regulatory preparation, clinical validation, and FDA submission fees. Teams that want to make clinical claims should budget for this before building the product, not after.

If you are unsure whether your intended claims trigger SaMD classification, the FDA's Digital Health Center of Excellence publishes guidance and runs a pre-submission program where you can get informal feedback before committing to a regulatory pathway.

How women's health platforms make money

According to a 2023 report by Grand View Research, the global femtech market was valued at $5.1 billion in 2022 and is projected to grow at a compound annual rate of 15.5% through 2030. That growth reflects four distinct revenue models, each with different unit economics.

Consumer subscription is the most common entry point. Flo has reported annual recurring revenue above $100M. Clue operates a freemium model where basic cycle tracking is free and advanced features require a subscription at $4.99-$9.99/month. Natural Cycles charges $14.99/month or $99.99/year. Subscription models require sustained consumer marketing investment and face high churn in the first 30 days if the core prediction accuracy is poor.

Employer and health plan B2B contracts price on a per-employee-per-month basis. The typical PEPM range for a women's health digital benefit is $2-$8, depending on the depth of the offering and whether it includes telehealth access. Contract values are larger than consumer subscription, sales cycles run 3-9 months for enterprise deals, and retention is driven by utilization reporting and renewal conversations with HR benefits teams, not individual user satisfaction.

Clinical SaaS for fertility clinics prices on a per-provider or per-patient-per-month basis. A fertility clinic using a custom patient-facing app as part of its IVF workflow can justify $30-$80 per patient per active cycle, because the alternative is nursing staff time spent on manual patient communication. At a clinic doing 400 IVF cycles per year, that is a clear ROI calculation.

De-identified data licensing is a revenue stream that several women's health companies have explored. Aggregate, anonymized cycle and fertility data has value to pharmaceutical companies, insurers, and research institutions. However, reproductive health data carries special privacy sensitivity that limits this model. Post-Dobbs, any data licensing program that involves reproductive health data faces scrutiny from privacy advocates, regulators, and the users themselves. The architecture required to produce genuinely de-identified reproductive health data at scale is significant, and the reputational risk of any re-identification event is high.

How RaftLabs builds women's health apps

"Women's health builds have two layers of compliance that most digital health teams conflate," says Ashit Vora, co-founder of RaftLabs. "HIPAA is the floor. Reproductive data privacy architecture is a separate requirement that most teams discover only when their legal counsel reviews the data flows after the app is already built. Every women's health engagement we scope starts with a data architecture session before any product design work, because the decisions made in that session determine whether the app can serve an employer, a health plan, or a clinical institution without creating liability."

We have built clinical-grade digital health products across telehealth, patient engagement, care coordination, and fertility technology. For women's health platforms, the first engagement is a scoping session that maps the care or wellness model, the population, and the integration requirements to a data architecture decision tree. That session produces a V1 scope that is clinically defensible, privacy-compliant in the post-Dobbs landscape, and extensible to the clinical claims or employer integrations that come in V2 or V3.

If you are building a patient-facing fertility app for a clinical network, an employer women's health benefit with population-level reporting, or a consumer reproductive health platform where privacy architecture is your market differentiation, book a 30-minute scoping call. We will scope your V1, identify the regulatory decisions you need to make before building, and tell you what it costs.